Brooks Laboratories Limited reports Q1 FY27 results; Consolidated entity faces loss from joint venture
Brooks Laboratories Limited has released its Unaudited Financial Results for the quarter ending June 30, 2026, providing details of both standalone and consolidated performance across two business segments.The company's results reflect operations in Trading and Manufacturing segments. The financial statements provide a granular look at revenues, expenses, and segment-wise profitability for the period.
Consolidated Financial Overview (Quarter Ended June 30, 2026)
On a consolidated basis, the company reported Total Income of 2,313.75 Lakhs for the quarter. The Net Profit attributable to Owners of Equity was recorded at (178.69) Lakhs.A significant factor impacting the consolidated results is the share of loss from its jointly controlled entity. Brooks Steriscience Limited—a jointly controlled entity—recorded revenue from operations of 1,751.30 lakhs for the quarter ending June 30, 2026, resulting in a loss after tax of Rs. 654.18 lakhs. Consequently, the Company’s share of this loss amounted to Rs. 320.55 lakhs and was recognized in the financial statements.
Segment Performance Analysis
The company operates through Trading and Manufacturing segments, each showing distinct results for the quarter ended June 30, 2026.The segment results indicate:
- Manufacturing: Reported a profit of 185.10 Lakhs.
- Trading: Recorded a loss totaling (13.79) Lakhs.
Details regarding revenues and profits before share of loss from associates for both segments are provided below.
| Particular | Trading Segment | Manufacturing Segment | Total Consolidated Result |
|---|---|---|---|
| Profit/(Loss) before Share of Joint Entities & Tax | 141.86 Lakhs | 265.06 Lakhs | 141.86 Lakhs |
| Share of Loss from Jointly Controlled Entity | - | (320.55) Lakhs | (320.55) Lakhs |
| Profit/(Loss) before Exceptional Item & Tax | 141.86 Lakhs | 265.06 Lakhs | (178.69) Lakhs |
Segment Revenue and Asset Allocation
The segment revenue breakdown for the quarter ended June 30, 2026, was as follows:| Segment | Trading Revenue (Lakhs) | Manufacturing Revenue (Lakhs) |
|---|---|---|
| Consolidated | 18.53 | 2,277.55 |
| Standalone | 2,296.08 | 0 |
The total assets for the entity stood at 14,654.02 Lakhs, comprised of segment assets and unallocated amounts, showing a strong allocation in both trading (4,925.22 Lakhs) and manufacturing (9,728.80 Lakhs).
Key figures from the statement are summarized in the table below:
| Financial Metric | Standalone Results (Quarter Ended June 30, 2026) | Consolidated Results (Quarter Ended June 30, 2026) |
|---|---|---|
| Total Income | 2,313.75 Lakhs | 2,296.08 Lakhs |
| Profit/(Loss) after Tax Attributable to Owners of Equity | (178.69) Lakhs | (178.69) Lakhs |
BROOKS Stock Price Movement
As of 3:12 PM, Brooks Laboratories Limited sees its shares shed ₹3.28 or 5.00%, currently trading at ₹62.32 following a slide from yesterday's close. The stock has seen significant activity in the live market, with 33,535 shares traded so far this afternoon.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.